Aurinia Pharmaceuticals(US:AUPH) Yahoo Finance·2026-03-01 09:27Financial Performance - Aurinia Pharmaceuticals Inc. reported total revenue of $77.1 million for Q4 2025, a 29% increase from $59.9 million in Q4 2024, and $283.1 million for the full year 2025, up 20% from $235.1 million in 2024 [1] - Net product sales of LUPKYNIS reached $74.2 million for Q4 2025, a 29% increase from $57.6 million in Q4 2024, and $271.3 million for the full year 2025, up 25% from $216.2 million in 2024 [2] Cash Position and Share Repurchase - As of December 31, 2025, Aurinia had cash, cash equivalents, restricted cash, and investments totaling $398.0 million, an increase from $358.5 million in the prior year [3] - The company repurchased 12.2 million common shares for $98.2 million during 2025 [3] Future Outlook - For 2026, Aurinia expects total revenue between $315 million and $325 million, representing an 11% to 15% increase compared to 2025, and net product sales between $305 million and $315 million, up 12% to 16% from 2025 [3] Company Overview - Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of therapeutic drugs [4]